Table 3 First (interim) PET/CT SUVmax (nodal and extra-nodal) and international prognostic index factors between final treatment responder and non-responder groups after 24 months
Final Responder (n = 23) | Final Non responder (n = 10) | Test of significance | P value | |
|---|---|---|---|---|
First PET/CT nodal SUVmax median (min–max) | 2.0 (1.3–25.1) | 8.7 (1.8–20.0) | Z = 2.31 | 0.02* |
First PET/CT extra-nodal SUVmax (median-max) | 1.9 (1.5–23.4) | 11.1 (1.5–34) | Z = 2.51 | 0.012* |
Age (Years) | χ2 = 2.56 | 0.109 | ||
< 60 years | 18 (78.3%) | 10 (100.0%) | ||
≥ 60 years | 5 (21.7%) | 0 (0%) | ||
Initial disease Stage | χ2 = 0.676 | 0.411 | ||
I & II | 15 (65.2%) | 5 (50.0%) | ||
III & IV | 8 (34.8%) | 5 (50.0%) | ||
Serum LDH | χ2 = 2.65 | 0.103 | ||
Normal | 14 (60.9%) | 3 (30.0%) | ||
High | 9 (39.1%) | 7 (70.0%) | ||
Extra-nodal involvement | FET | 0.291 | ||
0–1 site | 21 (91.3%) | 7 (70.0%) | ||
More than one site | 2 (8.7%) | 3 (30.0%) | ||
Performance status | χ2 = 5.99 | 0.014* | ||
0–1 | 19 (82.6%) | 4 (40.0%) | ||
02-Apr | 4 (17.4%) | 6 (60.0%) | ||
International risk category | χ2 = 5.18 | 0.023* | ||
Low risk | 20 (87.0%) | 5 (50.0%) | ||
High risk | 3 (13.0%) | 5 (50.0%) |